2.4 mg semaglutide to tirzepatide Troubling Findings in Study of GLP-1 Compounders typical dosing for tirzepatide Dosage

That's what made this Weather.com story so compelling

The article's comparison table lists tirzepatide as a dual GLP-1 and GIP agonist with a half-life of roughly five days, against semaglutide as a GLP-1 receptor agonist with a subcutaneous half-life of about seven days

Vomiting, diarrhea, and constipation follow similar patterns to semaglutide, typically resolving within weeks

National Health Service: How to Cope With Depression The New Anti-Obesity Drugs: What You Should Know Cleveland Clinic: Centers for Disease Control and Prevention: Diabetes and Mental Health Harvard Health Publishing: Weighing in on Weight Gain From Antidepressants Adam Gilden, MD, MSCE Medical Reviewer Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me